Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease.
Alzheimer's disease
Aβ oligomers
Cognitively impaired aged Beagle dogs
Disease-modifying therapy
Pharmacodynamics
Pharmacokinetics
Sporadic AD animal model
Tau oligomers
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
24
01
2023
revised:
14
07
2023
accepted:
18
07
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Disease-modifying therapies to treat Alzheimer's disease (AD) are of fundamental interest for aging humans, societies, and health care systems. Predictable disease progression in transgenic AD models favors preclinical studies employing a preventive study design with an early pre-symptomatic treatment start, instead of assessing a truly curative approach with treatment starting after diagnosed disease onset. The aim of this study was to investigate the pharmacokinetic profile and efficacy of RD2 to enhance short-term memory and cognition in cognitively impaired aged Beagle dogs - a non-transgenic model of truly sporadic AD. RD2 has previously demonstrated pharmacodynamic efficacy in three different transgenic AD mouse models in three different laboratories. Here, we demonstrate that oral treatment with RD2 significantly reduced cognitive deficits in cognitively impaired aged Beagle dogs even beyond the treatment end, which suggests in combination with the treatment dependent CSF tau oligomer decrease a disease-modifying effect of RD2 treatment.
Identifiants
pubmed: 37609390
doi: 10.1016/j.heliyon.2023.e18443
pii: S2405-8440(23)05651-7
pmc: PMC10440458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e18443Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dieter Willbold reports a relationship with Priavoid GmbH that includes: board membership. Dieter Willbold has patent issued to Priavoid GmbH. Co-founder and co-owner of Priavoid GmbH.
Références
Cell Rep Med. 2022 May 17;3(5):100630
pubmed: 35584626
Molecules. 2017 Oct 10;22(10):
pubmed: 28994710
NPJ Parkinsons Dis. 2022 Jun 2;8(1):68
pubmed: 35655068
Alzheimers Dement (N Y). 2020 Mar 20;6(1):e12001
pubmed: 32211506
Biochim Biophys Acta. 2013 Sep;1832(9):1384-9
pubmed: 23528711
Learn Mem. 2003 Mar-Apr;10(2):148-60
pubmed: 12663753
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1953-8
pubmed: 16446437
Front Aging Neurosci. 2022 Oct 10;14:937486
pubmed: 36299608
Neurobiol Learn Mem. 2007 Sep;88(2):249-59
pubmed: 17587610
Clin Biochem. 2017 Mar;50(4-5):244-247
pubmed: 27823959
J Neurosci. 2004 Sep 22;24(38):8205-13
pubmed: 15385603
Biochemistry. 2011 Jun 14;50(23):5172-81
pubmed: 21506544
Sci Rep. 2017 Nov 24;7(1):16275
pubmed: 29176708
Neurobiol Aging. 2008 Jan;29(1):39-50
pubmed: 17092609
Behav Neurosci. 1994 Feb;108(1):57-68
pubmed: 8192851
Mol Neurobiol. 2019 Mar;56(3):2211-2223
pubmed: 30003517
FEBS Lett. 2018 Feb;592(4):516-534
pubmed: 29360176
Behav Neurosci. 1995 Oct;109(5):851-8
pubmed: 8554710
Neurobiol Dis. 2019 Apr;124:36-45
pubmed: 30391539
Learn Mem. 2003 Jan-Feb;10(1):64-73
pubmed: 12551965
Learn Mem. 1999 Jan-Feb;6(1):54-61
pubmed: 10355524
J Alzheimers Dis. 2013;34(4):985-94
pubmed: 23313925
Vet Clin Pathol. 2019 Sep;48(3):400-405
pubmed: 31237714
ACS Chem Neurosci. 2019 Dec 18;10(12):4800-4809
pubmed: 31710458
J Alzheimers Dis. 2016 Jul 27;54(1):79-88
pubmed: 27472876
Acta Neuropathol. 2006 Aug;112(2):175-83
pubmed: 16775693